Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06938386 · ClinicalTrials.gov registry record · NA

Pilot Haskap Metabolite Timing Project

A NA study of Metabolic Disease and Microbial Colonization, sponsored by Montana State University.

Active
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT06938386: Active NA study of Metabolic Disease and Microbial Colonization, sponsored by Montana State University.

NCT06938386 is a NA study of Metabolic Disease and Microbial Colonization that is active but no longer recruiting, run by Montana State University. The registered enrollment target is 10 participants, below the 4,189-participant average among 33 other Metabolic Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06938386, a NA study of Metabolic Disease and Microbial Colonization, is active but no longer recruiting, sponsored by Montana State University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

Diet is a key factor in managing health and individuals at risk of developing metabolic syndrome or other chronic diseases have the opportunity to use diet as a tool to improve their health. This can be complicated when considering the numerous variables that impact digestion and absorption of key health-promoting compounds in foods. One of these variables is the gut microbiome, a microbial community in the digestive tract that interacts with the foods we consume. The mechanisms the microbiome uses to interact with bioactive compounds in foods, like polyphenols, can modulate the health-promoting benefits of polyphenols. Polyphenols are secondary plant metabolites, commonly found in fruit, legumes, chocolate, coffee, and nuts among other foods that have been shown to improve cardiovascular and metabolic health, as well as reduce inflammation and oxidative stress.

Primary Outcome

Relative abundance of metabolites and degradation products of Haskap berries

Interventions

  • DIETARY_SUPPLEMENT Haskap

Study Locations (1)

Montana

  • Montana State University - Bozeman

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2025-05-01
Est. Completion 2025-11-01
Phase NA
Montana State University

36 total trials

What the registry record for NCT06938386 still lists

NCT06938386 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 4,189-participant average among 33 other Metabolic Disease trials with a reported enrollment target (100% lower).

The record links to 3 conditions, with Metabolic Disease appearing as the primary indexed condition, and to 1 intervention - of which Haskap is the first listed.

NCT06938386 reports a single indexed study location in Montana.

Frequently Asked Questions

What is clinical trial NCT06938386 about?

NCT06938386 is a clinical study titled "Pilot Haskap Metabolite Timing Project". Diet is a key factor in managing health and individuals at risk of developing metabolic syndrome or other chronic diseases have the opportunity to use diet as a tool to improve their health. This can be complicated when considering the numerous variables that impact digestion and absorption of key h...

What is the current status of trial NCT06938386?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2025-05-01. Estimated completion is 2025-11-01.

What conditions does trial NCT06938386 study?

This clinical trial studies the following conditions: Metabolic Disease, Microbial Colonization, Digestion.

What interventions are being tested in trial NCT06938386?

The interventions under investigation include: Haskap (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06938386?

This trial is sponsored by Montana State University, which has 36 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06938386 being conducted?

This trial has 1 study location across Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metabolic Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06938386's enrollment target sits among peer trials

10 34th of 33 the lowest of 33 other Metabolic Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metabolic Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06938386, the US trial registry maintained by the National Library of Medicine. NCT06938386 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.